Treatment for XLH comes in two major categories:
- Surgical or orthopedic treatment.
Treatment almost always should take place at major research centers because of the rare nature of this disorder, and The XLH Network strongly suggests relying on specialists familiar with the condition and experienced in treating and managing it. These are most often endocrinologists or nephrologists with an interest in metabolic bone disorders.
Medications used in treating XLH – typically an active form of Vitamin D [such as Rocaltrol (Calcitriol) or ONE-ALPHA®] and phosphorus (such as K-PHOS®, Neutra-Phos®, or PHOSPHATE-SANDOZ®) – should be prescribed very carefully and taken in association with regular monitoring of blood and urine chemistries, including ParaThyroid Hormone (PTH) levels and urine calcium levels. The focus should not be on how high the phosphorus level can increase, as might be appropriate for other causes of a low blood phosphorus level, because in XLH the more phosphate you take, the more you eliminate in the urine, and the higher the PTH may go...which you will want to avoid. The medication can result in a variety of important effects on the kidneys that specialists will want to keep under tight control.
Progress is often measured in years, rather than months, so this can be very frustrating for parents and children alike. And if it’s not effective, or diagnosis came very late, surgical or orthopedic intervention may be required.
The XLH Network Inc. does not prescribe or suggest any particular treatment – that should be done by medical professionals and specialists in bone metabolism. These notes are provided based on the personal experience of members.
Source: The XLH Network Board of Directors
© 2011, The XLH Network Inc.
The authors of this web site are not medical professionals, and this information does not substitute for medical care. Information on these pages is based on biomedical research, published in peer-reviewed journals, and international research conferences. Additionally, in some cases anecdotal information is provided by subscribers of the F-HYPDRR group, a mailing list for The XLH Network Inc. A listing of XLH research is available. Please read our full disclaimer.
- XLH Network Survey
- The XLH Network is currently in a year-long process of working to grow our organization and better meet the needs of the XLH community. As part of our initiatives, we have designed a survey in hopes of getting feedback from our members. Your feedback…
- 2013 Rare Disease Day Symposium
- In February the 2013 Rare Disease Day Symposium was held in California at the Sanford-Burnham Medical Research Institute. This year's topic was "Calcification Disorders - from Hardened Arteries to Soft Bones". Amo…
- New National Institutes of Health Research Study
- NIH Research Study: Open-label Dose-titration Study of the Tolerability and Efficacy of Cinacalcet to Treat Fibroblast Growth Factor 23 (FGF23)-mediated HypophosphatemiaPrincipal Investigator: Dr. Rachel Gafni, MDSponsoring Institute: Craniofacial and Ske…
- Scientific Advisory Board member wins award at ASBMR
- Michael Econs, XLH Network Scientific Advisory Board Member (SAB), was awarded the Frederic C. Bartter Award for outstanding clinical investigation in disorders of bone and mineral metabolism at the American Society for Bone and Mineral Research…